Which SGLT2 Inhibitor to Choose
For this patient with type 2 diabetes, eGFR ≥45 mL/min/1.73 m², already on metformin and glipizide, you should add an SGLT2 inhibitor with proven kidney or cardiovascular benefit—specifically canagliflozin, dapagliflozin, or empagliflozin.
Recommended SGLT2 Inhibitors with Evidence-Based Benefits
The 2022 ADA/KDIGO consensus explicitly states that an SGLT2i with proven kidney or cardiovascular benefit is recommended for patients with T2D, CKD, and eGFR ≥20 mL/min/1.73 m² 1. At this patient's eGFR level (≥45 mL/min/1.73 m²), all three agents with outcome trial data are appropriate:
First-Tier Options (Listed by Strength of Kidney Evidence):
Canagliflozin 100 mg daily - Demonstrated kidney protection in CREDENCE trial specifically in diabetic nephropathy with albuminuria 1
Dapagliflozin 10 mg daily - Proven efficacy in DAPA-CKD trial down to eGFR 25 mL/min/1.73 m², with benefits regardless of albuminuria status 1
Empagliflozin 10 mg daily - Shown cardiovascular and kidney benefits in EMPEROR trials, effective down to eGFR 20 mL/min/1.73 m² 1
Not Recommended:
- Ertugliflozin - Lacks dedicated cardiovascular or kidney outcome trial data and is not recommended with eGFR <45 mL/min/1.73 m² 1
Dosing Considerations at This eGFR Level
Since your patient has eGFR ≥45 mL/min/1.73 m²:
- All three evidence-based SGLT2is can be initiated at standard doses without restriction 1
- Start at the doses tested in outcome trials (listed above)—no titration needed for cardiovascular/kidney protection 2
- Glucose-lowering efficacy remains intact at this eGFR level, though it diminishes as kidney function declines 1
Critical Management Steps Before and After Initiation
Before Starting:
- Reduce glipizide dose or discontinue - The patient is at risk for hypoglycemia when adding SGLT2i to sulfonylurea therapy 1. Consider reducing glipizide from 5 mg twice daily to 2.5 mg once daily, or stopping it entirely if HbA1c is near target
- Assess volume status - If patient is on diuretics or has risk factors for hypovolemia, consider reducing diuretic dose proactively 1
- Counsel on genital hygiene to reduce mycotic infection risk (occurs in ~6% vs 1% placebo) 1
After Initiation:
- Expect transient eGFR decline of ~5 mL/min/1.73 m² within first 2-4 weeks—this is hemodynamic, reversible, and NOT a reason to stop therapy 3, 1
- Continue SGLT2i even if eGFR later falls below 45 mL/min/1.73 m²—kidney and cardiovascular benefits persist 1
- Monitor for euglycemic DKA especially during acute illness—educate patient to hold SGLT2i during prolonged fasting, surgery, or critical illness 1
Key Safety Considerations
Common pitfalls to avoid:
- Don't stop SGLT2i for initial eGFR dip - This represents beneficial hemodynamic changes (afferent arteriolar vasoconstriction reducing glomerular hyperfiltration) 4, 5
- Don't wait for worsening kidney function - Benefits are greatest when started earlier in CKD course 1
- Maintain low-dose insulin if patient later requires it - Never completely discontinue insulin in insulin-requiring patients on SGLT2i due to DKA risk 1
Why These Three Agents Specifically?
The evidence hierarchy is clear: only canagliflozin, dapagliflozin, and empagliflozin have demonstrated kidney and cardiovascular outcome benefits in dedicated trials 1. The 2022 KDIGO guideline explicitly states to "prioritize agents with documented kidney or cardiovascular benefits" 3, 6. Ertugliflozin lacks this evidence base and has more restrictive eGFR limitations 1.
The choice among the three evidence-based options can be guided by:
- Local formulary availability and cost
- Presence of albuminuria (canagliflozin and dapagliflozin have strongest evidence in albuminuric CKD) 1
- Concomitant heart failure (all three effective, but empagliflozin and dapagliflozin have HF-specific indications) 2
Given equal efficacy for kidney and cardiovascular protection, any of the three evidence-based SGLT2is is appropriate—select based on practical considerations like insurance coverage and patient preference 6.